Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire

Robert P. Baughman*, Elyse E. Lower, Mindy Buchanan, Paola Rottoli, Marjolein Drent, Jacobo Sellares, Michelle Terwiel, Marjon Elfferich, Joel Francesqui, Maria Rita Barriuso Cabrerizo, Nadera Sweiss, Filippo Martone, Tamara Al-Hakim, Marc A. Judson

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: It has been suggested that sarcoidosis patients, especially those on immunosuppressive medications, are at increased risk for COVID-19 infection and more severe disease. Methods: A questionnaire was developed in four languages (English, Dutch, Italian, and Spanish). The questionnaire queried whether patients had been infected with COVID-19 and outcome of the infection. Risk factors for COVID-19 infection were collected. Results: A total of 5200 sarcoidosis patients completed the questionnaire with 116 (2.23%) reporting infection and 18 (15.8%) required hospitalization. Increased hazard ratio (HR) for COVID-19 infection were seen for those with a COVID-19 infected roommate (HR=27.44, p

Original languageEnglish
Article number2020009
Number of pages12
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Volume37
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • COVID-19
  • sarcoidosis
  • immunosuppression

Cite this